The ubiquitin ligase APC/C Cdh1 coordinates degradation of key cell cycle regulators. We report here that a nuclear-localized portion of the stress-activated kinase JNK is degraded by the APC/C Cdh1 during exit from mitosis and the G1 phase of the cell cycle. Expression of a non-degradable JNK induces prometaphase-like arrest and aberrant mitotic spindle dynamics. Moreover, JNK phosphorylates Cdh1 directly, during G2 and early mitosis, changing its subcellular localization and attenuating its ability to activate the APC/C during G2/M. This regulatory mechanism between JNK and Cdh1 reveals an important function for JNK during the cell cycle.
RESULTS

JNK protein levels are regulated by proteolysis in a cell-cycledependent manner
Recently we reported the presence of a KEN box, a motif found in APC/C substrates, in all JNK isoforms described so far in mammals 20 (Fig. 1a ), prompting us to analyse JNK stability during the cell cycle. Analysis of JNK expression in HeLa cells synchronized by a double-thymidine block (which arrests cells at the beginning of S phase) revealed that JNK protein levels are indeed reduced during exit from mitosis and G0/G1 phase ( Fig. 1b and Supplementary Information, Fig. S1a, b ). We also observed similar changes in JNK expression levels through the cell cycle in T98G, U2OS, IMR90, HFF-1 and MEF cells that were cell-cycle-synchronized ( Supplementary Information, Fig. S1c ). Cell cycle synchronization in HeLa cells was confirmed biochemically by analysis of cyclin B1 and Plk-1 levels, which are mainly targeted for proteolysis by APC/C Cdc20 and APC/C Cdh1 , respectively (Fig. 1b ). Cells expressing low levels of ectopic JNK also show cell-cycle-dependent fluctuations in JNK levels ( Fig. 1c and Supplementary Information, Fig. S1d, e ), suggesting that changes in JNK levels during the cell cycle are primarily post-translational. Indeed, JNK mRNA levels during the cell cycle were largely unchanged ( Supplementary Information, Fig. S1f ).
To directly assess cell cycle-related changes in JNK stability, we first used in vitro extracts prepared from HeLa cells synchronized either by a doublethymidine block or by nocodazole-arrest. Only extracts prepared from cells exiting from mitosis or in G0/G1 phase could induce degradation of exog-enous JNK ( Fig. 1d and Supplementary Information, Figs S1g and S2a). Consistent with these findings, we also observed that the half-life of endogenous JNK is regulated in a cell-cycle-dependent manner in both synchronized HeLa and HFF-1 cells ( Supplementary Information, Fig. S3a-d) .
Interestingly, we noted that the timing of JNK degradation in different experimental settings coincides with APC/C Cdh1 activation during the mammalian cell cycle 13, 21 . To examine cell-cycle-associated degradation of JNK by Cdh1, we used Xenopus laevis egg extracts, which recapitulate cell cycle transitions in vitro 22 . JNK was stable in mitotic (cytostatic factor, CSF) extracts, extracts undergoing metaphase-anaphase transition (calcium-treated CSF extracts, which activate the APC/C Cdc20 ), and interphase extracts (Inter; Fig. 1e ). Nevertheless, addition of Cdh1 to interphase extracts (which activates APC/C Cdh1 ) was sufficient to cause JNK disappearance. Furthermore, treatment with MG-132 blocked Cdh1-induced JNK degradation in interphase extracts (Fig. 1e ). These data indicate that cell-cycle-dependent degradation of JNK is mediated by APC/C Cdh1 and proteasomes.
Fine tuning of JNK protein levels by Cdh1
To confirm that the JNK KEN box acts as a key molecular determinant responsible for JNK degradation 20 , we analysed the stability of a JNK mutant whose KEN box had been either deleted (JNK ΔKEN ) or mutated (JNK AAA ). In vitro kinase assays showed that neither deletion nor mutation of the KEN box affected JNK kinase activity (Supplementary Figure 1 JNK is degraded in vivo and in vitro in a cell cycle-and KEN box-dependent manner. (a) Multi-alignment of a selected protein sequence from the ten members of the human JNK family. Highlighted in italics and underlined is the activation loop (amino acids 183-185, in JNK2α2); in bold and underlined is the KEN box (amino acids 203-205, in JNK2α2) and underlined a putative Destruction-box (D-box; amino acids 295-298, in JNK2α2). (b) Extracts prepared from HeLa cells were synchronized by a double-thymidine block (DTB) and analysed over a period of 18 h by immunoblotting using the indicated antibodies (*54K, JNK2; + 46K, JNK1). FACS analysis confirming the synchronization is shown in Supplementary Information, Fig. S1a . (c) Synchronized HeLa cells overexpressing either HA-tagged JNK2 (wild-type or mutants) or HA-tagged JIP1 (JNK interacting protein 1) or control-transfected cells were analysed by immunoblotting with antibodies against HA-tag, cyclin B1 or tubulin. Quantification of JNK2 (wild-type or mutants) levels for each synchronization is shown on the graph. (d) JNK2 in vitro degradation assays in concentrated extracts prepared from HeLa cells released after being synchronized by either DTB (left panels) or nocodazole arrest (right panels). FACS data are included in Supplementary Information, Fig. S1g . (e) JNK2 in vitro degradation assays in Xenopus egg extracts. Uncropped images for key results of this figure are shown in Supplementary  Information, Fig. S7 . nature cell biology VOLUME 12 | NUMBER 7 | JULY 2010 6 8 7
Information, Fig. S2b ). Importantly, expression of either JNK ΔKEN or JNK AAA revealed that both are refractory to degradation in vitro ( Fig. 1e and Supplementary Information, Fig. S2c ) and in vivo ( Fig. 1c and Supplementary Information, Fig. S1e ). In contrast, deletion of a putative D-box (JNK ΔD-box mutant) had only a mild effect on JNK stabilization (Fig. 1c , e and Supplementary Information, Fig. S1e ). Together, these results indicate that APC/C Cdh1 mediates cell-cycle-dependent degradation of JNK through the KEN box. Consistent with the role of Cdh1 in JNK degradation, pulldown assays using recombinant, bacterially produced, tagged JNK, and radiolabelled Cdh1 produced in rabbit reticulocyte lysates, revealed that JNK interacts in vitro with Cdh1 ( Fig. 2a and Supplementary Information, Fig. S2d ). Conversely, recombinant Cdh1 (produced and purified from insect cells) was able to pulldown radiolabelled JNK produced in reticulocyte lysates ( Fig. 2a , lower panels). Further, co-immunoprecipitation assays using either overexpressed or endogenous components confirmed that JNK is associated with Cdh1 in vivo ( Supplementary Information, Fig. S2e, f) . Importantly, a robust interaction between endogenous Cdh1 and JNK proteins was cell-cycle-dependent, and occurred specifically during exit from mitosis and G1 phase of the cell cycle ( Fig. 2b ), when the APC/ C Cdh1 is known to be activated. Finally, in vitro assays revealed that APC/ C Cdh1 could ubiquitylate JNK ( Fig. 2c and Supplementary Information, Fig. S2g ). These data suggest that JNK levels are regulated by APC/C Cdh1mediated ubiquitylation and subsequent proteasomal degradation.
Our experiments in Xenopus egg extracts suggest that Cdh1 is the limiting factor required for cell-cycle-dependent degradation of JNK. To test this possibility in mammalian cells, we monitored JNK levels after exogenous expression of Cdh1. Transient overexpression of Cdh1 resulted in efficient degradation of JNK, which was blocked by addition of MG-132 ( Fig. 2d ). Conversely, depletion of Cdh1 from cells by transfection of shRNA directed against Cdh1 (ref. 23 ) abolished the oscillation of JNK levels seen during the cell cycle ( Fig. 2e and Supplementary Information, Fig. S2h ). These findings strongly suggest that Cdh1 is required to regulate JNK degradation during the cell cycle.
Finally, to obtain a clearer understanding of the signalling pathway leading to JNK degradation, we assessed whether JNK isolated from either the nucleus or cytoplasm had different levels of stability in degradation assays in vitro. Our analyses revealed that nuclearlocalized JNK is more susceptible to Cdh1-induced degradation ( Fig. 3a ). Indeed, a JNK protein isolated from the nuclear compartment of cells synchronized before entry into mitosis, had the shortest half-life ( Fig. 3a ). Of note, JNK degradation was not detectable in cells subjected to UV-irradiation, suggesting that such degradation occurs in normally cycling cells but not after a genotoxic insult (data not shown). Interestingly, the kinase-deficient JNK mutant (JNK APF ) showed a similar pattern seen for the non-degradable version of JNK (JNK ΔKEN ), indicating that JNK phosphorylation (and activation) may be a prerequisite for its degradation (Fig. 3a) . These observations reveal that degradation of JNK requires the following: an intact KEN box; its prior activation (phosphorylation at amino acids Thr 183 and Tyr 185 referred to as the TPY motif); nuclear localization; and specific G2/Mdependent modification(s).
JNK activation and its role during the unperturbed cell cycle
Timely degradation of JNK, during exit from mitosis and the G1 phase of the cell cycle, suggests that its instability is required for cell cycle progression. As JNK is a kinase, it is plausible that it mediates timely phosphorylation of cell cycle regulatory proteins. To assess these possibilities, JNK activity was measured during the cell cycle. Interestingly, JNK activity per se (as monitored using a phospho-JNK antibody and in vitro kinase assays) was cell-cycle-regulated and restricted to G2 phase and early mitosis ( Fig. 3b ). Furthermore, we found that a fraction of JNK accumulates in the nucleus during G2 and early M-phase, and that accumulation correlates with JNK activation in the nuclear compartment ( Fig. 3c ).
Given that JNK activation is limited to G2 and early M-phase 20 , we hypothesized first, that downregulation of JNK activity during exit from mitosis is, in part, caused by JNK degradation; and second, that JNK activation during G2-M might be required for unperturbed cell cycle progression. To test these possibilities, we used the non-degradable mutant of JNK (JNK ΔKEN ). As noted above, we confirmed that this mutant has kinase activity in vitro ( Supplementary Information, Fig. S2b ) and can be activated during the cell cycle in vivo ( Fig. 4a Elevated levels of Wee1 have been correlated with low levels of Cdk1 activity independently of cyclin levels 24 . Thus, JNK may directly regulate Wee1 stability. Indeed, using either overexpressed or endogenous components, we found that JNK interacts with Wee1 in vitro and in vivo. However, in vitro phosphorylation assays using bacterially purified and active Wee1 and JNK revealed that neither kinase is a substrate for the other ( Supplementary Information, Fig. S5a -g). These findings suggest that the JNK effect on Wee1 is probably indirect and could be mediated by members of the Cdc25 family 20 . 
JNK controls microtubules and mitotic spindle dynamics
Given the increase in total mitotic index observed in both HFF-1 and HeLa cells expressing the JNK ΔKEN mutant ( Fig. 4c and Supplementary  Information, Fig. S4c ), we used immunofluorescence to analyse their mitotic spindle and chromosomal dynamics. HFF-1 cells that had the most significant G2/M arrest after expression of the JNK ΔKEN mutant also had aberrant microtubular structures reminiscent of collapsed mitotic spindles ( Fig. 5a ). Furthermore, to determine whether JNK ΔKEN -expressing cells were impaired in entry into or exit from mitosis, or both ( Fig. 5b ), we performed live-cell imaging using HFF-1 or HeLa cells expressing JNK WT or mutant JNK ΔKEN . Analyses of movies recorded using these cultured cell lines ( Fig. 5c and Supplementary Information, Movies 1-6) revealed that entry into mitosis was delayed in JNK ΔKEN -expressing cells; instead these cells showed a clear prometaphase-like arrest, characterized by highly condensed DNA that failed to align into a metaphase plate (a prerequisite for its proper segregation during progression through mitosis). Furthermore, we confirmed that prometaphase-like arrest induced by JNK ΔKEN is mostly attributable to kinase activity generated by this mutant protein in cells, as arrest was rescued by low doses of a peptidic JNK inhibitor ( Fig. 5d ). Finally, a significant increase in aberrant mitotic figures, including monopolar and multipolar spindles and misaligned and metaphasic lagging chromosomes were noted in HeLa cells, which were more resistant to JNK ΔKEN -induced G2/M arrest (Fig. 5e ). These data establish that inhibition of JNK degradation, coupled with its unrestrained activity throughout the cell cycle, affects entry into mitosis, which is accompanied by abnormal mitotic microtubular and chromosomal structures. nature cell biology VOLUME 12 | NUMBER 7 | JULY 2010 6 9 1
JNK directly phosphorylates and regulates Cdh1
We observed a significant delay in the kinetics of cyclin B1 degradation in synchronized HFF-1 and HeLa cells expressing the JNK ΔKEN mutant, despite only a modest G2/M arrest (Fig. 4a-c and Supplementary  Information, Fig. S4a-c ), suggesting that JNK hyperactivation might directly affect APC/C. In addition, in vitro and in vivo assays revealed interaction between JNK and Cdh1 ( Fig. 2a, b and Supplementary Information, Fig. S2d-f ). We therefore asked whether JNK contributes to Cdh1 regulation. Indeed, in vitro kinase analysis revealed that JNKs can phosphorylate Cdh1 within its amino-terminal regulatory domain ( Supplementary Information, Fig. S6a ). Detailed mutagenesis analysis, including all putative S/TP sites located in the N terminus of Cdh1 (amino acids 1-215) identified Thr 32 and Ser 36 and 151 as JNK phosphoacceptor sites on Cdh1 in vitro (Fig. 6a ). To test for potential cross-talk between JNK-and Cdk-mediated Cdh1 phosphorylation, we analysed the precise kinetics of JNK, Cdk1 and Cdk2 activation during the cell cycle. We found that initial activation of JNK during the cell cycle preceded Cdk1
and was concomitant with Cdk2 ( Supplementary Information, Fig. S6b ). Significantly, in vitro analyses revealed that JNK and Cdk2 phosphorylate different residues at the Cdh1 N terminus (Supplementary Information, Fig. S6c ), whereas Cdk1 was able to phosphorylate all S/TP sites at the Cdh1 N terminus in vitro ( Supplementary Information, Fig. S6d, e ). Notably, Cdk1 phosphorylation of Cdh1 in vitro was enhanced when Cdh1 was initially phosphorylated by JNK, indicating that JNK phosphorylation of Cdh1 may prime its subsequent phosphorylation by Cdk1 ( Fig. 6b ).
To assess the effect of Cdh1 phosphorylation by JNK, we monitored possible changes in the ability of Cdh1 to activate APC/C. A prerequisite for Cdh1 contribution to APC/C activity is its interaction with the APC/C core complex 6 . Significantly, when we monitored the interaction between recombinant Cdh1 (either unphosphorylated or phosphorylated by JNK in vitro) and Cdc27 (a core subunit of the APC/C), we found that JNK-phosphorylated Cdh1 affinity for Cdc27 was significantly reduced in three different cell lines ( Fig. 6c ), which is expected to limit Cdh1dependent APC/C activity. Moreover, ubiquitylation assays indicated Extracts prepared from these fractions were analysed by Cdc27 immunoblotting and subjected to Cdh1 immunoprecipitation followed by Cdh1 and phospho-Thr Pro (pTP) immunoblotting. B23/nucleophosmin and PI(3)K serve as nuclear and cytoplasmic markers, respectively. Levels of JunB (whose reduction is a marker of G2-phase) were assessed in the 0 h (DBT) versus 6 h-released (G2) extracts, only for the control conditions. FACS analyses are also included. Uncropped images for key results of this figure are shown in Supplementary Information, Fig. S7 .
that JNK-phosphorylated Cdh1 is less capable of activating APC/C in vitro, compared with its unphosphorylated counterpart (Fig. 6d ). Consistent with these observations, we found that a fraction of Cdh1 relocates in the cytoplasm before mitosis in a JNK-dependent manner (Fig. 6e) . These observations reveal a mechanism for Cdh1 exclusion from APC/C core components in the presence of active JNK, thereby pointing to the role of JNK in the regulation of APC/C activity.
To test whether activation of JNK during the cell cycle (which occurs mainly in G2) also induces Cdh1 phosphorylation in cells, we synchronized HeLa cells and used a phospho-specific antibody ( Supplementary  Information, Fig. S6f ), raised against a phosphorylated-Thr 32/Ser 36-containing Cdh1 peptide. We found that Cdh1 phosphorylation at Thr 32 and Ser 36 probably occurred during G2 and early entry into mitosis, shortly before cyclin B1 readily accumulated in cells (Fig. 7) . Treatment of cells after release from S-phase arrest with either a peptidic JNK inhibitor or JNK1/2 shRNA abolished Cdh1 phosphorylation at Thr 32 and Ser 36 ( Fig. 7) . Furthermore, inhibition of Cdk1/2 activation during the cell cycle by roscovitine, a specific pan Cdk inhibitor, did not alter Cdh1 phosphorylation at Thr 32 and Ser 36 ( Fig. 7 ), suggesting that JNK is a bona fide kinase for Cdh1 during the cell cycle, which acts independently of Cdks.
JNK limits Cdh1 activation during cell cycle progression
We next assessed whether Cdh1 phosphorylation by JNK regulates cell cycle progression. Expression of the JNK ΔKEN mutant in cells correlated with enhanced phosphorylation and cytoplasmic localization of Cdh1 (Fig. 8a) . This result confirms that JNK-mediated Cdh1 phosphorylation affects its localization and therefore regulates the ability of Cdh1 to activate APC/C and recruit its bona fide substrates. Furthermore, expression of non-phosphorylatable forms of Cdh1, which are mutated in either the JNK or the Cdk2 phosphoacceptor sites characterized here, decreased steadystate levels of Cdc20, Plk-1 and cyclin B1, which are typical substrates of APC/C Cdh1 (Fig. 8b) , confirming that phosphorylation of Cdh1 by JNK Supplementary Information, Fig. S7 .
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(and Cdk2) negatively regulates its contribution to APC/C function. Moreover, induction of G2/M arrest, detected by FACS ( Fig. 8c) , indicates that ectopic expression of these non-phosphorylatable Cdh1 mutants was sufficient to impair cell cycle progression. Further, inhibition of JNK activity markedly reduced and delayed accumulation of cyclin B1 in HFF-1 and HeLa cells, respectively, phenotypes rescued by Cdh1 downregulation by shRNA ( Fig. 8d ; HeLa cells and Supplementary Information, Fig. S6g ; HFF-1 cells). Finally, we found that in MEFs obtained from JNK1/2 DKO animals, expression levels of cyclin B1 and Cdc20 were partially repressed, but could be restored by inhibition of Cdh1 activity (Fig. 8e) . These findings suggest that unrestrained activation of Cdh1 occurs during cell cycle progression in the absence of JNK activation.
DISCUSSION
Our study uncovers an unexpected link between JNK (a major stress kinase) and Cdh1 (an important cell cycle regulator) in the control of APC/C activity and cell cycle progression, through direct phosphorylation and inhibition of Cdh1 function. The observation that activation of endogenous JNK occurs during G2 and early M phase 20, 25, 26 suggests that JNK degradation is one of the mechanisms responsible for kinase inactivation after mitosis. Consistent with this possibility is the observation that activated JNK is preferentially targeted for degradation by APC/C Cdh1 . However, initial inactivation of JNK seems to start before its ubiquitylation and degradation by the APC/C Cdh1 . The latter suggests the existence of a JNK-specific phosphatase responsible for its inactivation during mitosis, thereby de-repressing the APC/C Cdh1 complex in conjunction with Cdh1 dephosphorylation mediated by the Cdc14 phosphatases [27] [28] [29] .
It is important to emphasize that the newly discovered function of JNK in cell cycle control is probably physiologically relevant under conditions in which JNK degradation is impaired. Such conditions could occur in settings where JNK expression and activity are constitutively Supplementary Information, Fig. S7 .
high, and would resemble phenotypes seen following expression of the JNK ΔKEN mutant 20 . Elevated JNK expression or activity, which is often seen in human tumours, could be attributable to increased transcription or impaired degradation, and mimic the effects of a non-degradable form of JNK, which deregulates cell cycle progression. In agreement, changes in Cdh1 expression or in the activity of the APC/C would result in increased JNK expression during the cell cycle. Consistent with the notion that JNK activity is important for cell cycle progression are findings that inhibiting JNK activity either by pharmacological inhibitors 30 or genetic deletion 31 impairs the G2-to M-phase transition or general cell cycle progression, respectively. Finally, histone H3, Aurora B, and Cdc25C were recently suggested to be regulated by the JNK pathway during the cell cycle 20, 25, 26 , indicating that JNK may contribute to additional cell-cycle-regulated processes.
Overall, our data establish that JNK levels and activity are tightly controlled during the cell cycle to ensure seamless entry into mitosis under normal growth conditions.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Cell cycle synchronization and cellular fractionation. HeLa nocodazolearrested cells were obtained by growth in nocodazole (330 nM) for 18 h. Release from M-phase arrest was accomplished by washes followed by growth in fresh medium. For double-thymidine-block, HeLa cells were grown in the presence of thymidine (2 mM) for 18 h and then released into thymidine-free media for 6-8 h and finally grown again for 12 h with thymidine before their final release from late G1-induced arrest. Cell cycle synchronization protocols for other cells employed were described elsewhere [36] [37] [38] [39] . Nuclear/cytosolic separation was performed using HeLa cells and the fractionation kit from BioVision (no. K266-25).
Antibodies.
Commercially available antibodies used were as follows: Cdh1 (DCS-266-Abcam) (used at 1:300 dilution), Cdh1/FZR (ZMD.02 clone-Invitrogen) (1:500), Plk1 (F-8-Santa Cruz) (1:300), cyclin B1 (GNS1-Santa Cruz) (1:300), cyclin B1 (V152-Cell Signaling) (1:1000), Cdk2 (M2-Santa Cruz) (1:500), Cdk1/Cdc2 (POH-1 clone-Abcam) (1:300), Flag (M2-Sigma) (1:2000), Cdc20 (ab2648-Abcam) (1:300), GFP (mouse-Zymed) (1:500), Ubiquitin (FL-76-Santa Cruz) (1:100), c-Myc (9E10-Santa Cruz) (1:300), Lamin A/C (636-Santa Cruz) (1:200), JunB (ab11981-Abcam) (1:200), and phospho-(Thr) MAPK/CDK substrate (2321-Cell Signaling) (1:1000) ( Supplementary  Information, Fig. S6f, bottom panels) . Antibodies to phosphorylated amino acids Thr 32 and Ser 36 on human Cdh1 were produced in rabbits immunized with keyhole-limpet haemocyanin-conjugated phosphopeptide. The phosphospecific antibodies were affinity purified (Phosphosolutions) and used at 1:250 dilution ( Supplementary Information, Fig. S6f , top panels). Antibodies to TOME-1 (used at 1:300 dilution) were produced in rabbits immunized with full-length TOME-1 protein tagged with GST (bacterially produced) (our unpublished results).
In vitro binding assays. Bacterially expressed and purified recombinant proteins, either GST or 6xHistidine tagged (1-5 μg) were pre-bound to 10 μl of glutathionesepharose beads (Amersham) or Nickel-NTA agarose beads (Qiagen) respectively, by incubation for 1 h at 4 °C on a rotating-wheel, followed by three washes with immunoprecipitation buffer (50 mM Tris-HCl, pH = 7.5, 150 mM NaCl, 0.5% NP-40, 5 mM EGTA, 5 mM EDTA, 20 mM NaF, 2 mM MgCl 2 , 100 μM sodium orthovanadate), supplemented with protease inhibitors as described previously 35 . These beads were then mixed with 5-10 μl of reticulocyte lysate (which was programmed to express the protein of interest, labelled with 35 S-methionine) in a total volume of around 500 μl of immunoprecipitation buffer. After incubation for 2 h at 4 °C on a rotating-wheel, the beads were gently centrifuged, washed three times with IP buffer and resuspended in 25 μl of 2X sample buffer. The beads were finally boiled for 5 min and subjected to SDS-PAGE, followed by Coomassie staining of the gels (to verify equal amounts of recombinant proteins in every sample), dried and analysed in a PhosphorImager (Fujifilm). The input lanes of the pulldown experiments typically correspond to 5% of the total radiolabelled sample used in the reaction mixture.
Immunoprecipitation experiments. Cell extracts were prepared in immunoprecipitation buffer. Equal amounts of protein extracts (calculated by Bradford's method) were incubated with either control IgGs or affinity-purified antibodies (0.5-1 μg) covalently bound to protein A-Sepharose beads. The mixture was incubated in a rotating-wheel for 1-2 h at 4 °C. The beads were gently centrifuged, washed three times with IP buffer and resuspended in 30 μl of 2X sample buffer. The beads were finally boiled for 5 min and subjected to SDS-PAGE and immunoblotting. In some cases, the beads were washed three times with IP buffer, twice with 50 mM Tris-HCl (pH = 7.5), and used for in vitro kinase reactions.
In vitro kinase assays. All reactions (for JNK, Cdk1, and Cdk2) were performed with immunoprecipitated samples, total extracts, or bacterially purified recombinant proteins in the so-called histone H1 kinase (H1K) buffer (commonly used to test the activity of Cdks in vitro 35 ), in the presence of adequate substrates (1-5 μg) and 32 P-γ-ATP.
In vitro degradation assays. Experiments performed in Xenopus laevis egg extracts were done according to published protocols 35, 40 . Experiments using HeLa cells concentrated extracts were described elsewhere 36 . Briefly, 1-2 μl of in vitro translated and 35 S-labelled JNK protein (prepared using pET15b-JNK2α2 and the rabbit reticulocyte TNT system (Promega)) were incubated in 20-30 μl of the desired extract and incubated at 30 °C during the reported kinetics. Analysis and quantifications were performed using a Fluorescent-Image Analyzer FLA-5100 and the Multi-Gauge software (Fujifilm).
In vitro ubiquitylation assays. JNK ubiquitin assays by the APC/C were performed following protocols published previously 35, 36, 41, 42 . Briefly, 35 S-labelled JNK or cyclin B1 from reticulocyte lysates (2 μl per time point) were incubated at 30 °C with 5 μl of a reaction mixture containing 1 mg ml -1 bovine ubiquitin (Sigma), 0.5 μg of ubiquitin-activating E1 enzyme (a gift from Olivier Coux, CRBM-CNRS, Montpellier, France), 0.5 μg of either GST-UbcH5B or GST-UbcH5C (E2), 10 mM Tris-HCl (pH = 7.5), 100 mM KCl, 5 mM MgCl 2 , MG-132 (50 μM), Ubiquitin-aldehyde (3 μM) and a standard ATP-regenerating cocktail 35 . APC/C was immunoprecipitated from HeLa cell extracts as described previously 36 and supplemented with Cdh1 protein produced in rabbit reticulocyte lysates. Reactions were stopped by adding sample loading buffer and were analysed by SDS-PAGE and PhosphorImaging.
Flow cytometry (FACS).
Cells were trypsinized and fixed in 70% ice-cold methanol for 20 min, washed in phosphate-buffered saline, and incubated for 30 min at 25 °C in propidium iodide (PI) buffer (10 mM Tris-HCl, pH = 7.4, 5 mM MgCl2, 50 μg of PI per ml, and 10 μg RNase A per ml). The stained cells were acquired by the FACSort flow cytometer (Becton Dickinson) and the DNA content was analysed using FlowJo software.
Immunoflurorescence microscopy. Cells were grown on coverslips and fixed with formaldehyde in PBS at 25 °C for 15 min. After fixation, samples were permeabilized with 0.5% Triton X-100 in PBS for 15 min and thereafter blocked with 10% FCS in PBS containing 0.01% Triton X-100. Coverslips were incubated for 1 h each at 25 °C with primary and secondary antibodies and mounted with Vectashield medium containing DAPI.
Time-lapse microscopy. HeLa, HeLa stably transfected with GFP-H2B or HFF-1 cells grown on 35-mm glass-bottom microwell dishes (MatTek) were transfected with pEF-Flag-JNK2 WT or pEF-Flag-JNK2Δ KEN mutant by nucleofection (Amaxa). Twelve hours after transfection, cells were cultured with CO 2independent medium (GIBCO) containing 10% FBS for 2 h. Dishes were then covered with mineral oil (Sigma) and transferred to a heated-stage (37 °C) on a Figure 1B. (B) Extracts prepared from HeLa cells which were synchronized by a DTB and analyzed after release over a period of 18 hours by immunoblotting using the indicated antibodies. TOME-1 has been described as a bona fide APC/C Cdh1 substrate (Ayad, N.G., Rankin, S., Murakami, M., Jebanathirajah, J., Gygi, S. & Kirschner, M.W. TOME-1, a trigger of mitotic entry, is degraded during G1 via the APC. Cell, 113(1) , 101-13 (2003) ). (C) JNK is degraded in vivo in a cell cycle-regulated manner in a variety of cell lines. Extracts prepared from the indicated cell cultures synchronized as described in Methods (by either SSB, serum starvation block, or a DTB) were analyzed during a period of 18 h after release by immunoblotting using the indicated antibodies. In general, times 0 correspond to a G0 or G1 arrest, the G2/M transition occurs between 6-12 h (mitosis between 8-12 h). Late time-points of 16-18 h are likely to correspond to the following G1 phase. HFF stands for (normal) human foreskin fibroblasts. (D) Expression levels of HA-JNK2 and FLAG-JNK2 (both wild-type and KEN-deleted mutant) proteins reached in asynchronous HeLa cells as compared to endogenous JNK levels. (E) Synchronized HeLa cells over-expressing either HA-tagged JNK2 (wild-type or mutants) or HA-tagged JIP1 (JNK Interacting Protein 1) or control-transfected cells, were analyzed by immunoblotting with antibodies against HA-tag or tubulin. Quantification of JNK2 (wild-type or mutants) levels for each synchronization is shown in the graph. (F) Cell cycle analysis of JNK2α2, GAPDH and topoisomerase IIα mRNAs in synchronized cells. Synchronized HeLa cells were obtained by nocodazole-induced arrest (NIA) and release. Total cellular RNA isolated from the cell extracts at the indicated times was subjected to RT-PCR analysis using specific primers for the different probes. (G) Flow cytometry analysis of cell cycle-synchronized HeLa cells, by either a double-thymidine block and release protocol (left panel) or a nocodazole-arrest and release protocol (right panel), employed in the experiments shown in Figure 1D . Of note, for the experiments (B) and (E) shown in this figure, cultured cells were grown at high confluency (above 85%) as opposed to the experiments described in Figures 1B-C (around 50% confluency) . We suspect that under high confluency conditions, a DTB induces a G0 arrest instead of a classical S-phase arrest (data not shown). (*) refers to the 54 kDa isoform of JNK2 and (+) refers to the 46 kDa isoform of JNK1. Figure S1 A Of note, in this experiment, cultured cells were grown at high confluency (above 85%). Under high confluency, a DTB seems to induce a G0 arrest (data not shown) instead of a classical S-phase arrest (only obtained in our hands under relatively low confluency -around 50%-, such as in the experiment described in Figure 1D ). (B) In vitro kinase assay using bacterially-purified recombinant JNK2 protein (either wild-type (wt), deleted in its KEN domain (ΔKEN), or mutated in its KEN domain to a triplet of alanines (KEN-AAA)) and a GST- Figure S7 Uncropped immunoblots (indicating molecular weight markers) of the key results described in the paper. Some of the full-sized membranes (or gels) were cut prior to immunoblotting (or exposure) according to molecular weight markers and probed with various antibodies to detect different proteins. 
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